Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.
Qi SN, Yang Y, Zhang YJ, Huang HQ, Wang Y, He X, Zhang LL, Wu G, Qu BL, Qian LT, Hou XR, Zhang FQ, Qiao XY, Wang H, Li GF, Zhu Y, Cao JZ, Wu JX, Wu T, Zhu SY, Shi M, Xu LM, Yuan ZY, Su H, Song YQ, Zhu J, Hu C, Li YX.
Qi SN, et al. Among authors: wu g, wu jx, wu t.
Am J Hematol. 2020 Sep;95(9):1047-1056. doi: 10.1002/ajh.25878. Epub 2020 Jul 16.
Am J Hematol. 2020.
PMID: 32449800
Free article.
Clinical Trial.